Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication

Abstract
Six patients with chronic hepatitis B virus(HBV)-induced liver disease were treated with human lymphoblastoid interferon. Daily, alternate day or thrice weekly regimens were employed in 2, 1 and 3 patients, respectively. Thrice weekly i.m. injections of 7.5 to 10 megaunits of interferon/m2 appeared to be as effective as daily injections in producing inhibition of HBV replication, were associated with fewer side effects and could be continued for up to 3 mo. The effectiveness of this regimen in producing long-term inhibition of viral replication must now be determined.